Detection of bioavailable peroxisome proliferator-activated receptor gamma modulators by a cell-based luciferase reporter system

Analytical Biochemistry

Volumn 427, Issue 2, 2012, Pages 187-189

  Del Bas, Josep M ^a   Laos, Sirle ^a   Caimari, Antoni ^a   Crescenti, Anna ^a   Arola, Lluís ^a,b  

^a TECNIO   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Bezafibrate; Bioavailability; Cell based luciferase assay; Metabolites; Nuclear receptors; PPAR ; RXR

Indexed keywords

BIOCHEMISTRY; CELLS; METABOLITES; MOLECULES;

BEZAFIBRATE; BIOAVAILABILITY; IN-VITRO ASSAYS; LUCIFERASE ASSAYS; LUCIFERASE REPORTER SYSTEM; NUCLEAR RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; REPORTER ASSAY;

CYTOLOGY;

BEZAFIBRATE; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; ASSAY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REPORTER GENE; SERUM;

RATTUS;

EID: 84862748467     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2012.05.005     Document Type: Article

References (9)

1. C. Gutierrez-Merino, C. Lopez-Sanchez, R. Lagoa, A.K. Samhan-Arias, C. Bueno, V. Garcia-Martinez, Neuroprotective actions of flavonoids, Curr. Med. Chem. 18 (2011) 1195-1212.
2. N.M. Delzenne, P.D. Cani, Interaction between obesity and the gut microbiota: relevance in nutrition, Annu. Rev. Nutr. 31 (2011) 15-31.
3. B.W. Ogilvie, D. Zhang, W. Li, A.D. Rodrigues, A.E. Gipson, J. Holsapple, P. Toren, A. Parkinson, Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of Cyp2C8: implications for drug-drug interactions, Drug Metab. Dispos. 34 (2006) 191-197. (Pubitemid 43042661)
4. M.M. McGrane, Vitamin A regulation of gene expression: molecular mechanism of a prototype gene, J. Nutr. Biochem. 18 (2007) 497-508. (Pubitemid 47043417)
5. L.S. Higgins, A.M. Depaoli, Selective peroxisome proliferator-activated receptor (PPAR) modulation as a strategy for safer therapeutic PPAR activation, Am. J. Clin. Nutr. 91 (2010) 267-272.
6. L. Villacorta, F.J. Schopfer, J. Zhang, B.A. Freeman, Y. Eugene, PPAR and its ligands: therapeutic implications in cardiovascular disease, Clin. Sci. 116 (2010) 205-218.
7. C.T. Eason, P. Powles, G. Henry, A.J. Spencer, A. Pattison, F.W. Bonner, The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat, Xenobiotica 19 (1989) 913-925. (Pubitemid 19212126)
8. P.J. Brown, D.A. Winegar, K.D. Plunket, L.B. Moore, M.C. Lewis, J.G. Wilson, S.S. Sundseth, C.S. Koble, Z. Wu, J.M. Chapman, J.M. Lehmann, S.A. Kliewer, T.M. Willson, A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR agonist with potent lipid-lowering activity, J. Med. Chem. 42 (1999) 3785-3788. (Pubitemid 29453459)
9. U. Abshagen, W. Bablok, K. Koch, P.D. Lang, H.A.E. Schmidt, M. Senn, H. Stork, Disposition pharmacokinetics of bezafibrate in man, Eur. J. Clin. Pharmacol. 16 (1979) 31-38. (Pubitemid 9235743)